Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shilei Ding

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Biorxiv : the Preprint Server for Biology|April 1, 2021
Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal EfficacyIrfan Ullah, Jérémie Prévost, Mark S Ladinsky, et al.
Immunity|August 28, 2021
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacyIrfan Ullah, Jérémie Prévost, Mark S Ladinsky, et al.
Cell Reports. Medicine|October 5, 2020
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 SpikeJérémie Prévost, Romain Gasser, Guillaume Beaudoin-Bussières, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Cross-sectional evaluation of humoral responses against SARS-CoV-2 SpikeJérémie Prévost, Romain Gasser, Guillaume Beaudoin-Bussières, et al.
Journal of Virology|April 7, 2025
Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaquesElise G Viox, Jonathan Richard, Andres G Grandea, et al.
Nature Medicine|December 10, 2021
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaquesPeng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
Iscience|December 14, 2022
Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBDYaozong Chen, Jérémie Prévost, Irfan Ullah, et al.
Cell Reports. Medicine|March 2, 2023
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4<sup>+</sup> T cell profileGérémy Sannier, Alexandre Nicolas, Mathieu Dubé, et al.
Nature Communications|May 16, 2024
Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunityElsa Brunet-Ratnasingham, Sacha Morin, Haley E Randolph, et al.
Mbio|January 11, 2023
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing AntibodiesFrederic Bibollet-Ruche, Ronnie M Russell, Wenge Ding, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Biorxiv : the Preprint Server for Biology|April 1, 2021
Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal EfficacyIrfan Ullah, Jérémie Prévost, Mark S Ladinsky, et al.
Immunity|August 28, 2021
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacyIrfan Ullah, Jérémie Prévost, Mark S Ladinsky, et al.
Cell Reports. Medicine|October 5, 2020
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 SpikeJérémie Prévost, Romain Gasser, Guillaume Beaudoin-Bussières, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Cross-sectional evaluation of humoral responses against SARS-CoV-2 SpikeJérémie Prévost, Romain Gasser, Guillaume Beaudoin-Bussières, et al.
Journal of Virology|April 7, 2025
Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaquesElise G Viox, Jonathan Richard, Andres G Grandea, et al.
Nature Medicine|December 10, 2021
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaquesPeng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
Iscience|December 14, 2022
Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBDYaozong Chen, Jérémie Prévost, Irfan Ullah, et al.
Cell Reports. Medicine|March 2, 2023
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4<sup>+</sup> T cell profileGérémy Sannier, Alexandre Nicolas, Mathieu Dubé, et al.
Nature Communications|May 16, 2024
Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunityElsa Brunet-Ratnasingham, Sacha Morin, Haley E Randolph, et al.
Mbio|January 11, 2023
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing AntibodiesFrederic Bibollet-Ruche, Ronnie M Russell, Wenge Ding, et al.
Pageof 12